Idec Eyes Success
Executive Summary
Troubles that made Idec drop its lead drug convinced it to take on manufacturing. From a stock price in June 1994 of $2.44 to a stock price of $24 in September 1996, whatever becomes of the products now coming through Idec's pipeline, the strategy that got it out of some bad times is worth a closer look.
You may also be interested in...
Biotechs on the Brink Choose Last-Minute Deals, Not Liquidation
Many biotechs, facing crisis situations in the fall of 2002, opted for deals that kept them alive but hardly offered much hope for upside. But in the coming months, boards may need to be far more realistic about their long-term prospects and consider a full range of options, including liquidation, when assessing a company's future.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.